Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H13NO |
Molecular Weight | 151.2056 |
Optical Activity | ( + ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)[C@@H](O)C1=CC=CC=C1
InChI
InChIKey=DLNKOYKMWOXYQA-IONNQARKSA-N
InChI=1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9+/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20553832Curator's Comment: description was created based on several sources, including
https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_14.htm | https://www.standort-ludwigshafen.basf.de/group/corporate/site-ludwigshafen/en/brand/CATHINE_HYDROCHLORIDE
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20553832
Curator's Comment: description was created based on several sources, including
https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_14.htm | https://www.standort-ludwigshafen.basf.de/group/corporate/site-ludwigshafen/en/brand/CATHINE_HYDROCHLORIDE
Cathine, known as D-norpseudoephedrine, is a psychoactive drug of amphetamine class, found naturally in Catha edulis (khat). It is a norepinephrine and dopamine releasing agent, and has thermogenic and anorectic effect. In the United States, cathine is classified as a Schedule IV controlled substance. Cathine hydrochloride is used as an appetite suppressant during the first few weeks of dieting to help establish new eating habits.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0048243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12954796 |
|||
Target ID: GO:0014046 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12954796 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CATHINE HYDROCHLORIDE Approved UseTreatment of obesity |
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves. | 2003 Jul |
|
Determination of ephedrine alkaloids in human urine and plasma by liquid chromatography/tandem mass spectrometry: collaborative study. | 2003 Jul-Aug |
|
Exemption of chemical mixtures containing the List I chemicals ephedrine, N-methylephedrine, N-methylpseudoephedrine, norpseudoephedrine, phenylpropanolamine, and pseudoephedrine. Final rule. | 2003 May 1 |
|
Determination of ephedrine alkaloids and synephrine in dietary supplements by column-switching cation exchange high-performance liquid chromatography with scanning-wavelength ultraviolet and fluorescence detection. | 2003 Sep 10 |
|
Determination of ephedra alkaloid and caffeine concentrations in dietary supplements and biological fluids. | 2004 Apr |
|
Concentrations of ephedra alkaloids and caffeine in commercial dietary supplements. | 2004 Apr |
|
Driving under the influence of khat--alkaloid concentrations and observations in forensic cases. | 2004 Feb 10 |
|
Determination of ephedra alkaloids in urine and plasma by HPLC-UV: collaborative study. | 2004 Jan-Feb |
|
Reference materials for analytical toxicology including doping control: freeze-dried urine samples. | 2004 May |
|
One internal standard for multiple analytes: a limit and solution. | 2004 Sep-Oct |
|
Common drugs of abuse--Part II. | 2004 Spring |
|
Simultaneous quantification of six ephedrines in a Mahwang preparation and in urine by high-performance liquid chromatography. | 2005 Jun |
|
A rapid and simple procedure for the determination of ephedrine alkaloids in dietary supplements by gas chromatography-mass spectrometry. | 2006 Aug 28 |
|
Electron ionization mass spectra of ephedrines in a doping confirmatory procedure: a curious migration of the trimethylsilyl group in the N-acetyl-O-trimethylsilyl derivatives. | 2007 |
|
Developmental patterns of phenylpropylamino alkaloids accumulation in khat (Catha edulis, Forsk.). | 2007 Dec 3 |
|
Risk assessment of khat use in the Netherlands: a review based on adverse health effects, prevalence, criminal involvement and public order. | 2008 Dec |
|
Miscellaneous. | 2008 Oct |
|
Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. | 2009 Apr |
|
The relevance of the urinary concentration of ephedrines in anti-doping analysis: determination of pseudoephedrine, cathine, and ephedrine after administration of over-the-counter medicaments. | 2009 Aug |
|
Population based prevalence of high blood pressure among adults in Addis Ababa: uncovering a silent epidemic. | 2009 Aug 23 |
|
The domino multicomponent allylation reaction for the stereoselective synthesis of homoallylic alcohols. | 2009 Feb 17 |
|
Keep an eye on the pupil: developing countries under chemical attack. | 2009 Jun |
|
Interpretation of urinary concentrations of pseudoephedrine and its metabolite cathine in relation to doping control. | 2009 May |
|
Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. | 2009 Nov 13 |
|
Influence of triiodothyronine on the contractile effect of D-nor-pseudoephedrine. | 2010 |
|
Long-term effects of chronic khat use: impaired inhibitory control. | 2010 |
|
Analysis of stimulants in oral fluid and urine by gas chromatography-mass spectrometry II: pseudophedrine. | 2010 May |
Sample Use Guides
As a component of khat, cathine is administered by chewing khat leaves. As a dietary supplement, cathine hydrochloride is administered orally, 20-50 mg once daily after breakfast for up to 4 wk. It is also available as oral drops.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12954796
For the NE release assay, whole rat brain minus cerebellum and caudate was homogenized in ice-cold 10% sucrose containing 1 uM reserpine. 50 nM GBR12935 and 100 nM citalopram were added to block [3H]MPP uptake into DA and 5-HT nerves. After 12 strokes with a Potter-Elvehjem homogenizer, brain homogenates were centrifuged at 1,000g for 10 min at 0–4°C, and the supernatants were retained on ice. Synaptosomal preparations were incubated to steady state with 5 nM [3H]MPP in a Krebs-phosphate buffer. After incubation to steady state, 850uL of synaptosomes preloaded with 3H ligand was added to test tubes that contained 150 uL of test drug. The release reaction was terminated by dilution with 4 ml of wash buffer followed by rapid vacuum filtration over GF/B filters. Retained tritium was counted by a liquid scintillation counter. L-Norpseudoephedrine was able to evoke NE release with EC50 of 15 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA08AA07
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
||
|
NCI_THESAURUS |
C221
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
||
|
WHO-ATC |
A08AA07
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
||
|
DEA NO. |
1230
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
32022
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | RxNorm | ||
|
DTXSID50889347
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
3389
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
CATHINE
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
441457
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
m8073
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | Merck Index | ||
|
C79914
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
492-39-7
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
CHEMBL1412041
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
E1L4ZW2F8O
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
DB01486
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
C005331
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
100000081373
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
m8687
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | Merck Index | ||
|
4952
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
207-754-1
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY | |||
|
SUB06158MIG
Created by
admin on Fri Dec 15 17:40:21 UTC 2023 , Edited by admin on Fri Dec 15 17:40:21 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)